New Radiomedicine Technology develops radiopharmaceuticals and produces medical isotopes for diagnosis and treatment in nuclear medicine. The company is advancing a pipeline of radiopharmaceutical candidates and plans to use new funding to carry those candidates through clinical trials. It also intends to invest in research, development, and production capacity for medical isotopes to strengthen its market position. Management has stated the financing will help consolidate its leading position in the domestic isotopes and radiopharmaceutical market. Backers and company leadership have framed radiopharmaceuticals as having significant potential in precision medicine and noted support from investors for industry coordination and technology self-reliance. The company is based in Chengdu and has existing shareholders such as Neovision Capital participating in the Series E round.

Total raised

$187M

Funding rounds

2

Latest round

Series E

Latest activity

Apr 2026